Price, DavidHenley, WilliamCarter, VictoriaSkinner, DVella, RebeccaPapi, A.Fabbri, Leonardo MKertsjens, HRoche, NSingh, DVogelmeier, CSen, ECancado, JNudo, ElenaBarile, SaraGeorges, George2024-04-082024-04-082022-03Price, D, Henley, W, Carter, V, Skinner, D, Vella, R, Papi, A, Fabbri, L M, Kertsjens, H, Roche, N, Singh, D, Vogelmeier, C, Sen, E, Cancado, J, Nudo, E, Barile, S & Georges, G 2022, 'Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone', Respirology, vol. 27, no. S1, TO 098, pp. 81. https://doi.org/10.1111/resp.142161323-7799https://hdl.handle.net/2164/23180Grant support: This study was funded by Chiesi Farmaceutici S.p.A. David Price has grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline.170613engR MedicineRJournal item10.1111/resp.1421627